Immunoblot Analysis of Serological Response to Pseudomonas Aeruginosa Septicaemia in Man

Overview

Journal J Clin Pathol

Specialty Pathology

Date 1986 Dec 1

PMID 3100581

Citations 3

Authors

R C Matthews

J P Burnie

S TABAQCHALI

Affiliations

Soon will be listed here.

Abstract

The occurrence of an outbreak of Pseudomonas aeruginosa septicaemias on an oncology ward permitted an analysis of antibody responses in patients who were all orally exposed to the same source of infection. Seven patients became septicaemic. Serial serum samples were immunoblotted against the homologous strain. Responses were compared with those of 16 other patients with septicaemias caused by other strains and 10 healthy controls. All 18 survivors produced increasing IgG or IgA antibody, or both, against a 35,000 dalton band, whereas these antibodies were usually absent or fell in titre in the five fatal cases. These antibodies were also lacking in sera taken just before a patient became septicaemic. This band had the electrophoretic characteristics of the outer membrane porin protein F.

Citing Articles

Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

Worgall S, Krause A, Rivara M, Hee K, Vintayen E, Hackett N J Clin Invest. 2005; 115(5):1281-9.

PMID: 15841217 PMC: 1070634. DOI: 10.1172/JCI23135.

Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of Pseudomonas aeruginosa.

Gilleland Jr H, Hughes E, Gilleland L, Matthews-Greer J, Staczek J Curr Microbiol. 1995; 31(5):279-86.

PMID: 7580798 DOI: 10.1007/BF00314580.

Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa.

Hughes E, Gilleland L, Gilleland Jr H Infect Immun. 1992; 60(9):3497-503.

PMID: 1379985 PMC: 257350. DOI: 10.1128/iai.60.9.3497-3503.1992.

References

Schimpff S, Moody M, YOUNG V . Relationship of colonization with Pseudomonas aeruginosa to development of Pseudomonas bacteremia in cancer patients. Antimicrob Agents Chemother (Bethesda). 1970; 10:240-4. View

Young L, Armstrong D . Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis. 1972; 126(3):257-76. DOI: 10.1093/infdis/126.3.257. View

Young L, Meyer R, Armstrong D . Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med. 1973; 79(4):518-27. DOI: 10.7326/0003-4819-79-4-518. View

HAGHBIN M, Armstrong D, Murphy M . Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia. Cancer. 1973; 32(4):761-6. DOI: 10.1002/1097-0142(197310)32:4<761::aid-cncr2820320405>3.0.co;2-h. View

Lugtenberg B, Meijers J, Peters R, van der Hoek P, van Alphen L . Electrophoretic resolution of the "major outer membrane protein" of Escherichia coli K12 into four bands. FEBS Lett. 1975; 58(1):254-8. DOI: 10.1016/0014-5793(75)80272-9. View

Miler J, Spilsbury J, Jones R, Roe E, Lowbury E . A new polyvalent Pseudomonas vaccine. J Med Microbiol. 1977; 10(1):19-27. DOI: 10.1099/00222615-10-1-19. View

Buchanan T, Pearce W, Schoolnik G, Arko R . Protection against infection with Neisseria gonorrhoeae by immunization with outer membrane protein complex and purified pili. J Infect Dis. 1977; 136 Suppl:S132-7. DOI: 10.1093/infdis/136.supplement.s132. View

Pollack M, Young L . Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest. 1979; 63(2):276-86. PMC: 371950. DOI: 10.1172/JCI109300. View

Hancock R, Carey A . Outer membrane of Pseudomonas aeruginosa: heat- 2-mercaptoethanol-modifiable proteins. J Bacteriol. 1979; 140(3):902-10. PMC: 216732. DOI: 10.1128/jb.140.3.902-910.1979. View

10.

Stephenson J, Heard S, Richards M, TABAQCHALI S . Gastrointestinal colonization and septicaemia with Pseudomonas aeruginosa due to contaminated thymol mouthwash in immunocompromised patients. J Hosp Infect. 1985; 6(4):369-78. DOI: 10.1016/0195-6701(85)90053-2. View

11.

HOMMA J . Roles of exoenzymes and exotoxin in the pathogenicity of Pseudomonas aeruginosa and the development of a new vaccine. Jpn J Exp Med. 1980; 50(3):149-65. View

12.

Jones R, Roe E, Gupta J . Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients. Lancet. 1980; 2(8207):1263-5. DOI: 10.1016/s0140-6736(80)92334-x. View

13.

Pincus D, Morrison D, Andrews C, Lawrence E, SELL S, Wright P . Age-related response to two Haemophilus influenzae type b vaccines. J Pediatr. 1982; 100(2):197-201. DOI: 10.1016/s0022-3476(82)80634-3. View

14.

Mutharia L, Nicas T, Hancock R . Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J Infect Dis. 1982; 146(6):770-9. DOI: 10.1093/infdis/146.6.770. View

15.

Cryz Jr S, Furer E, Germanier R . Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model. Infect Immun. 1983; 40(2):659-64. PMC: 264905. DOI: 10.1128/iai.40.2.659-664.1983. View

16.

Pollack M, Longfield R, Karney W . Clinical significance of serum antibody responses to exotoxin A and type-specific lipopolysaccharides in patients with Pseudomonas aeruginosa infections. Am J Med. 1983; 74(6):980-7. DOI: 10.1016/0002-9343(83)90795-7. View

17.

Lam J, Mutharia L, Hancock R, Hoiby N, Lam K, Baek L . Immunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis. Infect Immun. 1983; 42(1):88-98. PMC: 264528. DOI: 10.1128/iai.42.1.88-98.1983. View

18.

Bryan C, Reynolds K, Brenner E . Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis. 1983; 5(4):629-38. DOI: 10.1093/clinids/5.4.629. View

19.

Hedstrom R, PAVLOVSKIS O, Galloway D . Antibody response of infected mice to outer membrane proteins of Pseudomonas aeruginosa. Infect Immun. 1984; 43(1):49-53. PMC: 263386. DOI: 10.1128/iai.43.1.49-53.1984. View

20.

Cryz Jr S, Furer E, Germanier R . Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun. 1984; 43(3):795-9. PMC: 264250. DOI: 10.1128/iai.43.3.795-799.1984. View